SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin Cash is a hard fork of Bitcoin with a protocol upgrade to fix on-chain capacity. Bitcoin Cash intends to be a Bitcoin without Segregated Witness (SegWit) as soft fork, where upgrades of the protocol are done mainly through hard forks and without changing the original economic rules of the Bitcoin.  Bitcoin Cash (BCH) is released on 1st August 2017 as an upgraded version of the original Bitcoin Core software. The main upgrade is the increase in the block size limit from 1MB to 8MB. This effectively allows miners on the BCH chain to process up to 8 times more payments per second in comparison to Bitcoin. This makes for faster, cheaper transactions and a much smoother user experience.  Why was Bitcoin Cash Created?  The main objective of Bitcoin Cash is to to bring back the essential qualities of money inherent in the original Bitcoin software. Over the years, these qualities were filtered out of Bitcoin Core and progress was stifled by various people, organizations, and companies involved in Bitcoin protocol development. The result is that Bitcoin Core is currently unusable as money due to increasingly high fees per transactions and transfer times taking hours to complete. This is all because of the 1MB limitation of Bitcoin Core’s block size, causing it unable to accommodate to large number of transactions.  Essentially Bitcoin Cash is a community-activated upgrade (otherwise known as a hard fork) of Bitcoin that increased the block size to 8MB, solving the scaling issues that plague Bitcoin Core today.  Nov 16th 2018: A hashwar resulted in a split between Bitcoin SV and Bitcoin ABC

Bitcoin Cash

Bitcoin Cash is generating significant buzz as investors debate its long-term viability and potential for a breakout, with many in the community closely monitoring key technical support levels and recent price action. Conversations remain highly polarized, featuring a mix of speculative optimism regarding future upgrades and utility alongside skepticism from those who view the asset as underperforming relative to broader market movements.

$RARI is an ERC-20 token that controls the RARI Foundation treasury and governs the Rarible protocol and RARI Chain. The token was issued in 2020 with a max. supply of 25 million $RARI.

Rarible

Rarible is generating buzz as investors bet on its ultra-low supply and small market capitalization to trigger significant upward momentum, especially as the community eyes a potential NFT market recovery. Despite mixed sentiment regarding exchange listings, supporters are actively tracking technical breakouts and pushing for higher volume to ignite a rally.

Amplify ETF Trust - Amplify Alternative Harvest ETF

Amplify Alternative Harvest ETF

Amplify Alternative Harvest ETF is currently a focal point for investors speculating on potential federal marijuana rescheduling and regulatory reform in the U.S. Community members are actively debating the impact of upcoming elections and potential policy shifts on the sector, with many expressing frustration over persistent volatility while maintaining a long-term bullish outlook on eventual federal legalization.

Maul Coin

The MAULCOIN community is actively rallying behind the developer, emphasizing that this crypto project is a transparent, community-led alternative to common pump-and-dump schemes. While participants express frustration over the current lack of a price chart on major platforms, they remain highly engaged in raids and social media promotion to drive volume and secure future listings.

NeurAxis, Inc. engages in the provision of neuromodulation therapies to address chronic and debilitating conditions in children. Its product, IB-Stim, is a non-surgical device that works by sending gentle electrical impulses into cranial nerve bundles located in the ear. The company was founded by Gary Peterson and Christopher Robin Brown in 2011 and is headquartered in Carmel, IN.

Neuraxis Inc

NeurAxis is trending as investors react to its recent FDA clearance for its pediatric therapy, with the community actively debating whether the company will launch a stock offering or if the price action reflects a potential short squeeze. Traders are focused on the stock's low float and the long-term potential for institutional revenue growth as the company navigates its commercial rollout.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is seeing increased market activity as traders react to positive signals in the broader altcoin sector and renewed institutional interest, leading to significant social media buzz. Community discussions are heavily focused on the project's long-term potential, its quantum-resistant technology, and a general optimistic sentiment surrounding its future role in finance.

Sharplink, Inc. is an institutional-grade Ethereum treasury platform that provides public market investors with exposure to ETH. The platform focuses on Ethereum, which is used in various stablecoin, tokenized real-world asset, and decentralized finance settlement applications. This allows for native yield generation and potential network growth opportunities with ETH. The company is also involved in the online affiliate marketing business. The company was founded in 2019 and is headquartered in Miami, FL.

Sharplink Inc.

SharpLink Gaming Ltd

SharpLink Gaming is drawing attention as investors closely monitor its Ethereum treasury strategy and the significant discount to net asset value, fueling active community debate over the stock's long-term viability versus its recent downward price action. While some participants are capitalizing on the depressed levels as a contrarian opportunity, others remain skeptical about management's dilution practices and the overall performance of crypto-treasury holdings.

The Render Network is a leading decentralized GPU compute platform for applications ranging from 3D rendering to machine learning and generative AI.  The network connects node operators looking to monetize their idle GPU compute power with artists and developers looking to scale intensive 3D rendering work and machine learning applications in the cloud. Through a decentralized peer-to-peer network, the Render Network achieves unprecedented levels of scale, speed, and economic efficiency. Facilitated by the Render Network Foundation, the ecosystem empowers artists and developers to build services and applications for the emerging digital economy.

Render Token (SOL)

Render (RENDER) is gaining traction as investors capitalize on its critical role in the decentralized AI compute and DePIN sectors, where surging GPU demand and network efficiency following the Solana migration remain key talking points. The community is actively debating the tokens long-term utility versus short-term price volatility, with many users expressing conviction in its potential for substantial growth as institutional interest in AI infrastructure expands.

The TJX Cos., Inc. engages in the retail of apparel and home fashion products. It operates through the following business segments: Marmaxx, HomeGoods, TJX Canada, and TJX International. The Marmaxx segment sells family apparel including apparel, home fashions, and other merchandise. The HomeGoods segment offers an assortment of home fashions, including furniture, rugs, lighting, soft home, decorative accessories, tabletop and cookware as well as expanded pet, kids, and gourmet food departments. The TJX Canada segment operates the Winners, Marshalls, and HomeSense chains in Canada. The TJX International segment includes operations of T.K. Maxx and Homesense chains in Europe and the T.K. Maxx chain in Australia. The company was founded by Bernard Cammarata in 1962 and is headquartered in Framingham, MA.

TJX Companies, Inc.

TJX Companies is trending as investors monitor its resilience in a competitive retail landscape, specifically contrasting its steady off-price business model against the volatility seen in other major retail chains. The community is actively discussing the company's ability to drive traffic and maintain market share through its treasure-hunt shopping model while navigating broader concerns about potential tariff impacts and consumer spending shifts.

Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. Its products include CHEMOSAT and HEPZATO. The company was founded on August 5, 1988 and is headquartered in Queensbury, NY.

Delcath Systems Inc

Delcath Systems is trending due to its recent mixed Q3 earnings report, which highlighted solid revenue but resulted in a tempered fiscal outlook due to slower clinical site activation and a shift in 340B pricing. The community remains focused on the upcoming ESMO presentation of the CHOPIN trial data, viewing it as a major catalyst that could validate the Hepzato platform's synergistic potential and drive long-term value despite short-term market volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Innate Pharma to Participate in the Kempen Life Sciences Conference

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced...

Innate Pharma Files Its 2025 Universal Registration Document (Document Denregistrement Universel) and 2025 Form 20-f Annual Report

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced the filing of its 2025 Universal Registration Document (Document denregistrement...

Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Sees Large Decline in Short Interest

Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA - Get Free Report) saw a large decline in short interest in the month of March. As of March 13th, there was short interest totaling 76,183 shares, a...

Innate Pharma Q4 Earnings Call Highlights

Innate Pharma (NASDAQ:IPHA) outlined progress across its prioritized oncology pipeline and reviewed full-year 2025 financial results, emphasizing a streamlined strategy centered on three clinical...

Innate Pharma (NASDAQ:IPHA) Releases Earnings Results, Beats Expectations By $0.17 EPS

Innate Pharma (NASDAQ:IPHA - Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.35) by $0.17. The business had revenue of $2.42 million during the quarter, compared to...

Innate Pharma Reports Full Year 2025 Financial Results and Business Update

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today reported its business update and consolidated financial results for the year ending December 31...

Innate Pharma Announces Conference Call and Webcast for Full Year 2025 Financial Results

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company), today announces that the Company will hold a conference call on Thursday, March 26, 2026 at 2 p.m. CET...

Innate Pharma (IPHA) Projected to Post Earnings on Thursday

Innate Pharma (NASDAQ:IPHA) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 26. (View Earnings Report at...

Innate Pharma (IPHYF) Expected to Announce Quarterly Earnings on Thursday

Innate Pharma (OTCMKTS:IPHYF) will be releasing earnings before the market opens on Thursday, March 26. (View Earnings Report at...

Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Short Interest Update

Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA - Get Free Report) was the recipient of a significant decline in short interest in February. As of February 27th, there was short interest totaling...

Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. Its product pipeline includes Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Hervé Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié, and François Romagné on September 23, 1999 and is headquartered in Marseille, France.

Innate Pharma - ADR

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

Current Price	$1.37
Prev Close	$1.35
Open	$1.33
Dividend Yield	0.00%
50-Day Moving Average	$1.58
Beta	0.48
Avg. Volume	21,694.41
PE Ratio	-2.23

52-Week High	$2.63
52-Week Low	$1.17
Market Capitalization	$128.44M
EPS (Annual)	-$0.6195
Price to Book	-5.04
Revenue Per Employee	$19,296.61

IPHA
Innate Pharma

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest IPHA News

IPHAInnate Pharma